Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints – Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships

- Represents a 10-fold increase in the number of datapoints from one year ago, November 2020, and a 37-fold increase since the June 2020 IPO - Accelerates the discovery of new indications for Lantern's existing drug candidates, as well as the identification of new drug candidates and combination therapies - Data growth was largest in bladder, pancreatic, brain and blood cancers

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here